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Noroviruses account for 96% of viral gastroenteritis cases worldwide, with GII.4 strains responsible >80% of norovirus out-
breaks. Histo-blood group antigens (HBGAs) are norovirus binding ligands, and antigenic and preferential HBGA binding pro-
files vary over time as new GII.4 strains emerge. The capsid P2 subdomain facilitates HBGA binding, contains neutralizing anti-
body epitopes, and likely evolves in response to herd immunity. To identify amino acids regulating HBGA binding and antigenic
differences over time, we created chimeric virus-like particles (VLPs) between the GII.4-1987 and GII.4-2006 strains by exchang-
ing amino acids in putative epitopes and characterized their antigenic and HBGA binding profiles using anti-GII.4-1987 and
-2006 mouse monoclonal antibodies (MAbs) and polyclonal sera, 1988 outbreak human sera, and synthetic HBGAs. The ex-
change of amino acids 393 to 395 between GII.4-1987 and GII.4-2006 resulted in altered synthetic HBGA binding compared to
parental strains. Introduction of GII.4-1987 residues 294, 297 to 298, 368, and 372 (epitope A) into GII.4-2006 resulted in reactiv-
ity with three anti-GII.4-1987 MAbs and reduced reactivity with four anti-GII.4-2006 MAbs. The three anti-GII.4-1987 MAbs
also blocked chimeric VLP-HBGA interaction, while an anti-GII.4-2006 blocking antibody did not, indicating that epitope A
amino acids comprise a potential neutralizing epitope for GII.4-1987 and GII.4-2006. We also tested GII.4-1987-immunized
mouse polyclonal sera and 1988 outbreak human sera for the ability to block chimeric VLP-HBGA interaction and found that
epitope A amino acids contribute significantly to the GII.4-1987 blockade response. Our data provide insights that help explain
the emergence of new GII.4 epidemic strains over time, may aid development of norovirus therapeutics, and may help predict
the emergence of future epidemic strains.
Noroviruses (NoVs) are members of the Caliciviridae familyand represent the most significant cause of human acute viral
gastroenteritis worldwide (3). Approximately 23 million norovi-
rus infections occur each year in the United States alone (33),
burdening retirement homes, day cares, the military, cruise ships,
hospitals, educational institutions, and other community settings
where close contact between humans is unavoidable. The elderly,
very young, and immunocompromised are at the highest risk for
severe complications and death (32, 34, 36), and economic costs of
norovirus outbreaks are significant (23, 26). Although an esti-
mated 200,000 deaths occur each year from NoV-induced gastro-
enteritis (37), there are no approved vaccines or antiviral therapies
for the prevention or treatment of norovirus infections. However,
current clinical trials are encouraging and support the use of
virus-like particles (VLPs) of norovirus as a vaccine platform to
ameliorate the human disease burden (17).
Noroviruses carry a 7.5-kb single-stranded, positive-sense
RNA genome packaged within a 38-nm nonenveloped icosahe-
dral capsid. The genome carries three open reading frames
(ORFs). ORF1 encodes the replicase polyprotein, while ORF2 and
ORF3 encode the major (VP1) and minor (VP2) structural pro-
teins, respectively (13). Expression of VP1 from baculoviruses
(22) or Venezuelan equine encephalitis (VEE) (4) virus replicon
particles (VRPs) results in the production of NoV virus-like par-
ticles (VLPs). The capsid protein is divided into two distinct do-
mains in the virion, the shell (S) and the surface protruding do-
main (P). The P domain is further subdivided into the P1 and P2
subdomains, with the P2 subdomain flanked by portions of P1 in
the primary coding sequence (38). The shell forms the base of the
capsid, while the P1 region forms a stalk protruding from the shell.
The P2 subdomain is positioned atop the P1 stalk, where it is the
most surface-exposed region, able to interact with both carbohy-
drates (CHOs) and antibodies (9, 31). Histo-blood group antigens
(HBGAs) are a diverse family of CHOs expressed on mucosal
surfaces. These CHOs are differentially expressed in humans and
have been hypothesized to be receptors or coreceptors that allow
NoVs to attach to and enter permissive cells. Conserved amino
acids 343 to 345, 374, and 441 to 443 are important for HBGA
binding (9), although it is unclear how nearby amino acid varia-
tion affects capsid surface topology and contributes to HBGA
binding affinity differences noted in time-ordered GII.4 VLPs.
Partly because there is no cell culture or small-animal model for
human NoVs, the development and testing of vaccines and drug
treatments for NoVs have only recently been evaluated in larger
animal models of human disease (swine/primate models) (6, 44)
and in humans (17). Importantly, VLPs, created by the expression
of VP1 in a Venezuelan equine encephalitis (VEE) virus (4) or in
baculovirus (22) expression vector, are both physically and anti-
genically similar to norovirus virions. These systems offer a prom-
ising strategy to study norovirus structure and function, which
may lead to the development of effective vaccines and treatments
(30).
Noroviruses are a genetically diverse group of viruses, divided
into five genogroups (I to V) based on ORF2 sequence homology,
Received 31 August 2011 Accepted 1 November 2011
Published ahead of print 16 November 2011
Address correspondence to Ralph S. Baric, rbaric@email.unc.edu.
Copyright © 2012, American Society for Microbiology. All Rights Reserved.
doi:10.1128/JVI.06189-11
1214 jvi.asm.org 0022-538X/12/$12.00 Journal of Virology p. 1214–1226
in which protein sequence can differ by up to 60%. Each geno-
group is further divided into several genoclusters, differing by
20% to 30% in VP1 sequence (46). Genogroups I and II predom-
inantly encode strains that cause significant human disease (47).
Among these, genocluster GII.4 noroviruses account for 80% of
norovirus outbreaks (19). The emergence of new GII.4 NoV epi-
demic strains has been linked to changes in the HBGA binding
profile using synthetic ABH and Lewis (Le) CHOs (29). The 1974
strain, currently the prototypic ancestral strain, binds O-type
CHOs (H3 and Le-y) (5), the 1987 Camberwell strain binds
O-type CHOs (H3 and Le-y), while the 1997 Grimsby strain, a
pandemic strain, binds A trimer, B trimer, and O-type (H3 and
Le-y) CHOs. The Farmington Hills 2002 strain binds B trimer and
O-type (H3 and Le-y) CHOs (29). The most recent pandemic
strain, 2006 Minerva, binds A trimer, B trimer, and O-type (H3,
Le-b, and Le-y) CHOs (8). It is also clear that microvariation
within the P2 domain between closely related strains influences
CHO binding patterns (11, 14, 29, 41).
Among the GII.4 strains, the P2 region of ORF2 is evolving
more rapidly than other domains and subdomains of the GII.4
norovirus capsid protein, with certain amino acids undergoing
positive selection, likely in response to herd immunity (15, 29).
Antigenic changes are also evident over time, culminating in the
emergence of new GII.4 strains (15, 28, 42). On the capsid surface,
highly variable amino acids surround the binding pocket, altering
HBGA and antibody binding affinity. Multiple studies have iden-
tified specific residues within the P2 subdomain that are impor-
tant for antibody and HBGA interactions (1, 2, 29, 45). Linde-
smith et al. (29) showed that residues 393 to 395 are important for
HBGA interactions and antigenicity in GII.4 noroviruses (29). A
D393G change occurred between GII.4-1987 and GII.4-1997. Im-
portantly, introduction of the mutation D393G into the 1987
strain converted GII.4-1987 into a B binding VLP (29). In addi-
tion, two groups identified amino acids 296 to 298 as potentially
important for antigenicity and HBGA binding interactions (1,
15), and Allen et al. (1) demonstrated that these amino acids are
involved in strain-specific antibody recognition (2). However, it
was not clear whether antibodies targeting these sites blocked
VLP-CHO binding interactions, as a surrogate neutralization as-
say was not performed (2). Both of these amino acid clusters
(amino acids 296 to 298 and 393 to 395) comprise exposed loop
regions of the P2 subdomain. In addition, Tan et al. identified
amino acids 346 and 441 as important to A, B, and H binding and
showed that several other amino acids in and around the binding
pocket modulate HBGA specificity (45). A more recent study
based on comparing crystal structures from the GII.4-1996 and
GII.4-2004 strains suggests that temporal HBGA affinity differ-
ences exist among strains and that residues 393 to 395 directly
impact Lewis HBGA but not ABH HBGA binding (41). However,
the effects of amino acid differences at these positions may re-
model the conformational and electrostatic landscape around the
binding pocket, indirectly impacting ABH binding affinity. To-
gether, the previous data demonstrate that clusters of mutations
likely work independently or in concert to alter HBGA binding
profiles and antibody binding. However, the specific interactions
that take place to modulate HBGA binding and antigenicity are
still not well understood.
In this work, we designed and produced a panel of recombi-
nant and chimeric GII.4 NoV VLPs that exchanged surface-
exposed predicted epitopes between an ancestral GII.4 strain
(GII.4-1987, Camberwell) and the most recent pandemic GII.4
strain (GII.4-2006, Minerva). Our HBGA binding results provide
further evidence for the hypothesis that amino acids 393 to 395 are
important for HBGA A and B binding. Using a panel of mouse
monoclonal antibodies (MAbs) derived against GII.4-1987 or
GII.4-2006 (28) and human and mouse polyclonal sera, we em-
ployed gain- and loss-of-function assays to map varying antibody
blockade epitopes, which are potentially critical sites of virus neu-
tralization and protection from clinical disease (21, 29, 39). These
data implicate amino acids 296 to 298 as well as other nearby
amino acids that potentially contribute to antigenic differences
among time-ordered GII.4 strains that are likely associated with
escape from herd immunity. These data provide further support
for the hypothesis that the GII.4 viruses are evolving by epochal
evolution and antigenic variation in VP1 (15, 16, 29).
MATERIALS AND METHODS
Prediction of putative epitopes. Multiple sequence alignments were gen-
erated for all full-length GII.4 norovirus capsid peptide sequences in
GenBank using ClustalX, version 1.86 (12). A phylogenetic tree was gen-
erated by Bayesian inference using MrBayes (40), and 36 representative
sequences were selected and analyzed based upon unique phylogenetic
clustering characteristics. Representative strains of GII.4 noroviruses were
selected from 1974, 1987, 1997, 2002, 2004, 2005, 2006, 2007, 2008, and
2009. These representative sequences were aligned using ClustalX, version
1.86, P2 subdomain variation was exported into Excel, and amino acid
variation over time was analyzed. Homology models were generated using
Modeller (Max Planck Institute bioinformatics toolkit), building struc-
tural models based upon the crystal structure of V387 (Protein Data Bank
[PDB] accession no. 2OBT) (9) for each of the reference sequence P do-
mains. Variable sites that were potentially exposed on the surface of the
capsid were mapped and analyzed as these changes occurred over time
from 1974 to 2009. Five discrete regions were identified as putative
epitopes defined as local regions where clusters of amino acids map to
similar structural regions on the capsid surface.
Production of VLPs. Parental VLPs were expressed in a VEE expres-
sion system as previously described (4, 8, 29). Chimeric VLPs were created
by replacing the P2 subdomain of ORF2 in the parental strains with the
chimeric sequences (synthesized by BioBasic) (29). RNA was electropo-
rated into 1  107 BHK cells using Bio-Rad GenePulser Xcell pulsed 3
times with a voltage of 850 V, capacitance of 25 F, resistance of  , and
a cuvette size of 4 mm. Cells were then incubated for 24 to 28 h at 37° in
minimal essential medium (MEM)-alpha supplemented with 10% fetal
calf serum (FCS), 10% tryptose phosphate broth (TPB), 1% antibiotic/
antimycotic, and 1% nonessential amino acids (NEAAs). VLPs were har-
vested by spinning in 40% sucrose using a Ti-55 rotor at 31,500 rpm for 75
min. The sucrose cushion containing the VLPs was frozen at 80 degrees.
VLPs were quantified by protein assay and confirmed by electron micros-
copy (EM).
ELISAs. Enzyme-linked immunosorbent assays (ELISAs) were per-
formed as previously described (28). Briefly, enzyme immunoassay (EIA)
high-binding plates were coated with 100 l of 2 g/ml VLPs in
phosphate-buffered saline (PBS) and incubated for 4 h at room tempera-
ture. Plates were washed 3 times with PBS-0.05% Tween 20, then 100 l
5% Blotto was added to each well, and blocking was done overnight at
4°C. Plates were again washed 3 times with PBS-0.05% Tween 20, and 100
l 2 g/ml primary mouse MAb or a 1:500 dilution (1:500) of polyclonal
sera in 5% Blotto was added to each well and incubated at 37° for 45 min.
Following another wash as described above, 100 l secondary anti-mouse
AP antibody (Sigma, Jackson Laboratories) in 5% Blotto was added and
allowed to incubate at room temperature (RT) for 30 min. Plates were
again washed as described and detected using pNPP (Sigma). The values
used in this paper indicate binding in the linear portion of the binding
curve.
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CHO binding assays. CHO binding assays were performed as previ-
ously described (29). Briefly, avidin-coated plates were washed 3 times,
and 100 l 10 g/ml biotinylated CHO (GlycoTech) in 5% Blotto was
added to each well and incubated for 4 h. Plates were then washed 4 times
with a 15-s soak in PBS-Tween, and 100 l 2 g/ml VLP was added to each
well and incubated for 1.5 h at RT. Plates were washed 4 times with a 15-s
soak, and 100 l of 2 g/ml primary MAb or 1:1,000 polyclonal sera was
added and incubated for 45 min at RT. Plates were then washed 4 times
with a 15-s soak, and 100 l of 1:10,000 HRP-tagged anti-mouse antibody
(GE Healthcare) was added and incubated for 30 min at RT. CHO bind-
ing was measured by addition of 100 l Ultra TMB (3,3=,5,5=-
tetramethylbenzidine)-ELISA solution (Thermo Scientific). Sera and
mouse MAbs were produced as described previously (29).
Blockade assays. Blockade assays were performed as described previ-
ously (28). Briefly, NeutriAvidin-coated plates (Pierce, Rockford, IL)
were washed 3 times, and 100 l of 10 g/ml synthetic biotinyated-H3
CHO (GlycoTech, Gaithersburg, MD) in PBS was added to each well and
incubated for 1 h. VLP-mouse MAb dilutions (1 g/ml VLPs plus 2 g/ml
MAb) were prepared in a separate, nonbinding plate and incubated for 1
h. The avidin-coated plate was then washed 3 times, and VLP-Ab dilutions
were added and incubated for 1.5 h. The plate was then washed 4 times
with a 15-s soak, and 100 l of 2 g/ml anti-GII VLP rabbit polyclonal
antisera in 5% Blotto was added to each well and incubated for 30 min.
The plate was then washed 4 times with a 30-s soak, and 100 l of a
1:10,000 dilution of horseradish peroxidase (HRP)-tagged anti-rabbit IgG
antibody was added and incubated for 30 min. The plate was washed 4
times for 60 s and then developed by addition of 100 l TMB-ELISA
solution (Thermo Scientific) and 50 l stop solution. The plate was read at
an optical density of 450 (OD450). All incubations were done at room
temperature. Sera and mouse MAbs were produced as described previ-
ously (29).
Statistical analysis. Statistical analysis was performed using Prism
GraphPad, and results with P values of 0.05 were considered significant.
Two-way analysis of variance (ANOVA) was used to analyze CHO bind-
ing and MAb reactivity. One-way ANOVA was used to analyze the BT50s
(dilutions at which 50% of the VLP-CHO interaction is blocked com-
pared to the control) for blockade differences. Since GII.4-2006 was not
blocked even at the highest mouse serum concentration, individual rep-
licates not reaching the 50% blockade were assigned a BT50 value of 1:5 (2
times the highest serum concentration tested) for the purposes of statis-
tical analysis.
RESULTS
Multiple sequence alignments were generated for all full-length
GII.4 norovirus capsid genes in GenBank, and 36 representative
sequences were selected and analyzed, based upon unique phylo-
genetic clustering characteristics. Representative GII.4 norovirus
strains were selected from 1974, 1987, 1997, 2002, 2004, 2005,
2006, 2007, 2008, and 2009. These representative sequences were
aligned, and P2 subdomain variation was mapped upon homol-
ogy models of each protruding domain to identify variable sites
that were potentially exposed on the surface of the capsid and
therefore to the external environment. Five discrete regions (16,
19), two of which are discussed here, were identified as putative
epitopes defined as local regions where variation appears to cluster
on the surface (Fig. 1A and B). Putative epitope A is a conforma-
tional site comprised of amino acids 294, 296 to 298, 368, and 372,
and epitope D is an epitope comprised of contiguous amino acids
393 to 395. Of interest, position 394 is the site of a single amino
acid insertion that occurred in 2002 and has been fixed in the GII.4
NoV population since this time.
Design of the GII.4-1987 and -2006 chimeric VLPs. The P1
and P2 regions of the GII.4 NoV VP1 protein include residues that
undergo high levels of variability over time. Using a panel of time-
ordered mouse MAbs to GII.4-1987 and GII.4-2006 VLPs, we
demonstrated clear antigenic differences among GII.4 time-
ordered VLPs (28). To identify key varying residues that influence
HBGA and antibody binding, we created a panel of chimeric VLPs
by exchanging putative epitopes among strains that exhibit
unique HBGA CHO binding and antigenic characteristics (29).
GII.4-1987 (Camberwell) has previously been shown to bind syn-
thetic HBGA H3 (29), while GII.4-2006 (Minerva) binds synthetic
HBGAs A, B, and H3 (8). In this study, we focused on predicted
epitopes A and D, which are surface exposed and likely play im-
portant roles in either HBGA binding or antigenicity, or both (Fig.
1B). We used synthetic cDNAs and created a panel of chimeric
VLPs in which amino acids were exchanged between GII.4-1987
and GII.4-2006 within the identified putative epitopes (Fig. 1).
Expression of the GII.4 parental and chimeric VP1 genes resulted
in the production of robust levels of VLPs, as evidenced by SDS-
PAGE gel and electron microscopy (EM) (Fig. 1D).
Epitope D affects HBGA binding but not MAb antigenicity.
Putative epitope D includes amino acids 393 to 395, which are
surface exposed and vary greatly over time by either amino acid
variation or insertion (Fig. 1A and B). In GII.4-2002, an amino
acid insertion at position 394 evolved, which in later strains varied
over time and is present in GII.4-2006 but not GII.4-1987. Previ-
ous work in our lab demonstrated that amino acid 393 influenced
efficiency for HBGA B binding but not for A binding, suggesting
that other amino acids likely coordinate this HBGA interaction
(29). The Farmington Hills 2002a strain contains one change in
the P2 region at position 395 compared to the Farmington Hills
2002 strain. Farmington Hills 2002a is able to interact with HBGA
A, while Farmington Hills 2002 interactions are not robust, indi-
cating that residue 395 likely influences A binding (29). GII.4-
1987 has been shown to efficiently bind O-type CHOs but to only
weakly bind (or not at all) synthetic HBGAs A and B. GII.4-2006,
on the other hand, has been shown to efficiently bind O, A, and B
CHOs. We created chimeric VLP GII.4-2006(87D), in which we
introduced residues 393 to 395 from GII.4-1987 into the parental
GII.4-2006 strain and then built a reciprocal chimera, GII.4-
1987(06D), by inserting residues 393 to 395 from GII.4-2006
into the GII.4-1987 parental strain.
We performed a CHO binding assay to evaluate whether
epitope D chimeric VLPs GII.4-2006(87D) and GII.4-
1987(06D), in which amino acids 393 to 395 are exchanged,
would recapitulate HBGA binding characteristics of the parental
strains (Fig. 2A). As previously described, the GII.4-1987 parent
did not efficiently bind A or B CHOs, while the GII.4-2006 parent
bound both A and B in a time- and dose-dependent manner.
However, GII.4-2006(87D) did not bind to A or B, indicating
that the 2006 residues at these positions are important for the
ability of this strain to bind both HBGAs A and B. In addition,
GII.4-1987(06D) gained the ability to weakly bind HBGA A and
strongly bind HBGA B. Despite this gain of function, the binding
profile clearly differed from that of the GII.4-2006 parent, indicat-
ing there may be additional amino acids elsewhere in the capsid
that contribute to subtle remodeling of the affinity of HBGA A and
B interactions. These data are consistent with the idea that surface-
exposed residues in and around the conserved HBGA binding
sites influence HBGA binding efficiency (29, 41).
We were also interested in whether epitope D amino acids are
involved in antigenic differences between GII.4-1987 and GII.4-
2006. Our group previously characterized a large panel of time-
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ordered mouse monoclonal antibodies that display varying inter-
actions with time-ordered GII.4 VLPs (28). In particular, MAbs
GII.4-1987-G1, GII.4-1987-G2, GII.4-1987-G3, GII.4-1987-G4,
and GII.4-1987-G5 bound efficiently to GII.4-1987 but not to
GII.4-2006 VLPs, while MAbs GII.4-2006-G3, GII.4-2006-G4,
and GII.4-2006-G7 bound efficiently to GII.4-2006 but not to
GII.4-1987 VLPs (28). GII.4-2006-G2 primarily bound GII.4-
2006 but was somewhat cross-reactive with GII.4-1987 (28). The
availability of MAbs that recognize distinct epitopes on the sur-
faces of GII.4-1987 and -2006 VLPs provides a means of mapping
key residues that influence antibody escape from binding over
time. To determine if amino acids 393 to 395 contribute to anti-
genic differences between GII.4-1987 and GII.4-2006, we tested
the reactivity of these parents and chimeras with our panel of
GII.4-1987 MAbs and GII.4-2006 MAbs. While subtle differences
in overall binding were noted with anti-GII.4-1987 MAbs reacting
with GII.4-1987 compared to GII.4-1987(06D), we did not de-
tect significant differences in antigenic phenotypes between GII.4-
1987 and GII.4-1987(06D) or between GII.4-2006 and GII.4-
2006(87D) (Fig. 2B) with these characterized MAbs. These data
indicate that amino acids 393 to 395 do not explain the antigenic
differences observed between GII.4-1987 and GII.4-2006 for any
of the MAbs tested in our panel.
Putative epitope A amino acids contribute to antigenic dif-
ferences between GII.4-1987 and GII.4-2006. Putative epitope A
consists of closely positioned surface-exposed amino acids 294,
296, 297, 298, 368, and 372 (Fig. 1A and B). These amino acids
form a conformational cluster on the surface ridge of the capsid
and display charge variation over time, suggesting that these resi-
dues may play a key role in the escape from herd immunity. We
created chimeric VLPs in which combinations of amino acids 294,
297, 298, 368, and 372 from GII.4-1987 were introduced into the
GII.4-2006 backbone (Fig. 1C). While we attempted to create the
reciprocal exchange and produce VLPs comprised of GII.4-2006
FIG 1 Putative epitopes A and D. (A) Amino acid differences between GII.4-1987 Camberwell and GII.4-2006 Minerva in the P2 region of VP1. Green shading
indicates amino acids within putative epitope A, and orange indicates amino acids within putative epitope D. Shared residue 296S was included because it falls
within putative epitope A. (B) Epitope A is shown in green, consisting of 6 amino acids at positions 294, 296, 297, 298, 368, and 372. Epitope D is shown in orange,
consisting of 3 amino acids at positions 393 to 395. Black shading indicates the HBGA binding pocket. (C) Epitope A chimeric VLPs. The parental GII.4-2006 and
GII.4-1987 amino acid residues are shown in purple and yellow, respectively. GII.4-2006 Minerva residues (purple) were replaced in each chimera by GII.4-1987
Camberwell residues at the positions shown in yellow. A total of four epitope A chimeric VLPs were created. (D) Representative EM images of parental and
chimeric VLPs. (a) GII.4-1987; (b) GII.4-2006; (c) GII.4-1987(06D); (d) GII.4-2006(87D); (e) GII.4-2006(87A.1); (f) GII.4-2006(87A.2); (g) GII.4-
2006(87A.3); (h) GII.4-2006(87A.4).
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epitope A amino acids in the GII.4-1987 backbone, after multiple
tries, we were not able to yield VLPs that passed our quality con-
trol standards, which include robust protein production, as deter-
mined by SDS-PAGE gel and bicinchoninic acid (BCA) protein
assay, visualization of particles by EM, and the ability to bind
synthetic CHOs and one or more conformationally dependent
MAbs. The ability of these chimeras to bind anti-GII.4-1987
MAbs and anti-GII.4-2006 MAbs was measured and compared to
that of parental strains. As expected, GII.4-1987 VLPs demon-
strated strong homotypic reactivity, binding to anti-GII.4-1987-
G1, anti-GII.4-1987-G2, anti-GII.4-1987-G3, anti-GII.4-1987-
G4, and anti-GII.4-1987-G5, while GII.4-2006 did not react with
any of the GII.4-1987 MAbs tested (Fig. 3) (28). Chimeric VLP
GII.4-2006(87A.1), which contained all five of the epitope A
variable residues from GII.4-1987, exhibited significant increases
in reactivity with anti-GII.4-1987-G1, anti-GII.4-1987-G4, and
anti-GII.4-1987-G5, and this resulted in 6-fold, 14-fold, and 11-
fold increases in reactivity, respectively, compared to GII.4-2006
(Fig. 3) (P  0.0001). However, GII.4-2006(87A.1) did not sig-
nificantly alter binding (P  0.05) with the other two GII.4-1987
MAbs tested, anti-GII.4-1987-G2 or anti-GII.4-1987-G3, suggest-
ing the presence of another epitope located elsewhere on the vi-
rion (Fig. 3). Anti-GII.4-1987-G1, -G4, and -G5 have previously
been shown to be HBGA-VLP blocking antibodies (28), suggest-
ing that epitope A amino acids may comprise a neutralizing anti-
body epitope for GII.4-1987.
Binding of anti-GII.4-2006 MAbs was also compared between
GII.4-2006(87A.1) and parental strains GII.4-1987 and GII.4-
2006. GII.4-2006 had strong interactions with anti-GII.4-2006-
G2, anti-GII.4-2006-G3, anti-GII.4-2006-G4, and anti-GII.4-
2006-G7, while GII.4-1987 bound anti-GII.4-2006-G2 much less
efficiently than GII.4-2006 but did not bind anti-GII.4-2006-G3,
anti-GII.4-2006-G4, or anti-GII.4-2006-G7 (Fig. 3). Compara-
tively, GII.4-2006(87A.1) more closely resembled the binding
pattern seen for GII.4-1987. GII.4-2006(87A.1) exhibited an in-
termediate binding profile for anti-GII.4-2006-G2 that was
slightly greater than that seen for GII.4-1987 but greatly reduced
compared to GII.4-2006 (Fig. 3). GII.4-2006(87A.1) binding to
anti-GII.4-2006-G3 and anti-GII.4-2006-G4 was negligible, and
reactivity with anti-GII.4-2006-G7 was greatly reduced (Fig. 3).
Overall, binding of GII.4-2006(87A.1) was significantly reduced
compared to that of GII.4-2006 for all anti-GII.4-2006 MAbs
tested (P  0.0001).
Next, we evaluated whether GII.4-2006(87A.1) also had an
increased reactivity to GII.4-1987 mouse polyclonal sera. We per-
formed an ELISA comparing GII.4-2006(87A.1) reactivity with
both GII.4-1987 and GII.4-2006 polyclonal sera (Fig. 3). The
GII.4-1987 and GII.4-2006 parental strains bound most efficiently
to homotypic polyclonal sera, while GII.4-2006(87A.1) had a
significant, nearly 5-fold increase in binding to GII.4-1987 poly-
FIG 2 Epitope D chimeric VLP reactivity with synthetic HBGAs and anti-GII MAbs. (A) HBGA reactivity. Synthetic CHO was diluted to 10 g/ml and assayed
by the CHO binding assay for interaction with GII.4-1987, GII.4-2006, GII.4-1987(06D), and GII.4-2006(87D). Amino acid residues from GII.4-1987 were
exchanged with GII.4-2006 residues at positions 393 to 395. The dashed line represents 3 times the background level of binding and indicates a positive signal.
Asterisks indicate significant differences. (B) Anti-GII.4 MAb reactivity. Anti-GII.4-1987 and -2006 MAbs were diluted to 2 g/ml and assayed by EIA for
reactivity with GII.4-1987, GII.4-2006, GII.4-1987(06D), and GII.4-2006(87D) VLPs. Amino acid residues from GII.4-1987 were exchanged with GII.4-2006
at positions 393 to 395. Bars represent the mean optical density values with standard errors of the means. The dashed line represents 3 times the background level
of binding and indicates a positive signal.
FIG 3 GII.4-2006(87A.1) reactivity with anti-GII.4 MAbs. Anti-GII.4-1987
and -2006 IgG was diluted to 2 g/ml and assayed by EIA for reactivity with
GII.4-1987, GII.4-2006, and GII.4-2006(87A.1) VLPs. Amino acid residues
from GII.4-1987 were inserted into the GII.4-2006 backbone at positions 294,
297, 298, 368, and 372 to create GII.4-2006(87A.1). Bars represent the mean
optical density values with standard errors of the means. The dashed line
represents 3 times the background level of binding and indicates a positive
signal. Asterisks indicate significant differences.
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clonal sera (P  0.0001) and a significant 20% decrease in binding
to GII.4-2006 polyclonal sera (P  0.01) compared to the GII.4-
2006 parental VLP. However, GII.4-2006(87A.1) did not bind
to GII.4-1987 sera as strongly as the GII.4-1987 parental VLP.
These results confirm that GII.4-2006(87A.1) gained GII.4-
1987 reactivity but that there are additional amino acid residues
and/or epitopes (elsewhere on the capsid) that influence GII.4-
1987 antigenic space.
Epitope A amino acids do not influence HBGA A and B bind-
ing. To determine whether epitope A amino acids influence
HBGA A and B binding, we performed CHO binding assays using
GII.4-2006(87A.1) and compared the binding profile to those of
the parental GII.4-1987 and GII.4-2006 strains (Fig. 4). There
were no significant differences in HBGA A and B binding between
GII.4-2006(87A.1) and the parental strain GII.4-2006, indicat-
ing that these amino acids do not influence differences in HBGA A
and B binding between GII.4-1987 and GII.4-2006 under our
treatment conditions.
Fine resolution mapping. Putative epitope A consists of six
surface-exposed amino acid residues that cluster on the surface of
the virion. To further investigate the contribution of individual
and/or combinations of amino acids to antibody reactivity, we
characterized the antigenic profiles of additional chimeric VLPs in
which only one or two of the residue changes within epitope A
were switched between strains (Fig. 1C). Chimera GII.4-
2006(87A.2) contains two amino acid changes at positions
R297H and N298D. By ELISA, GII.4-2006(87A.2) did not react
with any of the anti-GII.4-1987 MAbs, except for displaying min-
imal reactivity with anti-GII.4-1987-G1, which was not signifi-
cantly different from the binding of the GII.4-2006 parent (Fig. 5).
In contrast, GII.4-2006(87A.2) reactivity with anti-GII.4-2006
was more similar to that of the GII.4-1987 parent, in that anti-
GII.4-2006-G3 and anti-GII.4-2006-G4 binding was ablated and
not significantly different from that of the GII.4-1987 parent. Un-
der identical conditions, binding to anti-GII.4-2006-G7 was sig-
nificantly reduced compared to the GII.4-2006 parent (Fig. 5)
(P  0.0001). This indicates that anti-GII.4-2006-G3, -G4, and
-G7 may target similar or overlapping epitopes in GII.4-2006
comprising amino acids 297 and 298. However, GII.4-
2006(87A.2), like GII.4-2006, exhibited strong binding with
anti-GII.4-2006-G2, indicating that GII.4-2006-G2 targets a dif-
ferent epitope than the other anti-GII.4-2006 MAbs in our panel;
this is in agreement with previous data from our lab (28). This
indicates that these amino acids modulate specificity to some anti-
GII.2006 MAbs but do not account for the gain of reactivity seen
with the additional amino acid substitutions in GII.4-
2006(87A.1).
Both chimeras GII.4-2006(87A.3) and GII.4-2006(87A.4),
which contain two amino acid changes at positions S368T and
E372N and one amino acid change at position A294V, respec-
tively, did not exhibit significantly different reactivity with anti-
GII.4-1987 or anti-GII.4-2006 MAbs compared with the GII.4-
2006 parent. GII.4-2006(87A.3) and GII.4-2006(87A.4) did
not react to any of the anti-GII.4-1987 MAbs but showed reactiv-
ity with all anti-GII.4-2006 MAbs (Fig. 6 and 7). Taken together,
our data indicate that all epitope A amino acids comprise a major
antigenic site for GII.4-1987 and that epitope A residues 297 and
FIG 4 Epitope A chimeric VLP reactivity with synthetic HBGAs. Synthetic
CHOs were diluted to 10 g/ml and assayed by the CHO binding assay for
interaction with GII.4-1987, GII.4-2006, and GII.4-2006(87A.1). Amino
acid residues from GII.4-1987 were inserted into the GII.4-2006 backbone at
positions 294, 297 to 298, 368, and 372. The dashed line represents 3 times the
background level of binding and indicates a positive signal.
FIG 5 GII.4-2006(87A.2) reactivity with anti-GII.4 MAbs. Anti-GII.4-1987
and -2006 IgG was diluted to 2 g/ml and assayed by EIA for reactivity with
GII.4-1987, GII.4-2006, and GII.4-2006(87A.2) VLPs. Amino acid residues
from GII.4-1987 were inserted into the GII.4-2006 backbone at positions 297
and 298 to create GII.4-2006(87A.2). Bars represent the mean optical density
values with standard errors of the means. The dashed line represents 3 times
the background level of binding and indicates a positive signal. Asterisks indi-
cate significant differences.
FIG 6 GII.4-2006(87A.3) reactivity with anti-GII.4 MAbs. Anti-GII.4-1987
and -2006 IgG was diluted to 2 g/ml and assayed by EIA for reactivity with
GII.4-1987, GII.4-2006, and GII.4-2006(87A.3) VLPs. Amino acid residues
from GII.4-1987 were inserted into the GII.4-2006 backbone at positions 368
and 372 to create GII.4-2006(87A.3). Bars represent the mean optical density
values with standard errors of the means. The dashed line represents 3 times
the background level of binding and indicates a positive signal.
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298 are important modulators of GII.4-2006 antigenicity (Table
1). Our data support the idea that several noncontiguous amino
acids work in concert to account for the antigenic differences be-
tween these strains.
Carbohydrate blockade. Based on previous work by Linde-
smith et al., anti-GII.4-1987-G1, anti-GII.4-1987-G4, and anti-
GII.4-1987-G5 are blocking antibodies for the same epitope in the
GII.4-1987 parent strain but do not block GII.4-2006 interaction
with synthetic CHOs (28). While we determined that GII.4-
2006(87A.1) gained binding to the anti-GII.4-1987-G1, -G4,
and -G5 MAbs (Fig. 3), we also determined whether these anti-
bodies were able to block the interaction between GII.4-
2006(87A.1) and HBGAs and thus whether epitope A amino
acids represented a possible neutralizing antibody epitope. To do
this, we performed a CHO blockade assay comparing the ability
of anti-GII.4-1987-G1, anti-GII.4-1987-G4, and anti-GII.4-
1987-G5 to block HBGA interactions with GII.4-1987, GII.4-
2006, and GII.4-2006(87A.1). While anti-GII.4-1987-G1, -G4,
and -G5 were not able to block GII.4-2006 interactions with H3
(28), all three MAbs were able to block H3 interactions with both
GII.4-1987 and GII.4-2006(87.1), indicating that these are
blocking antibodies for GII.4-2006(87A.1) and target epitope A.
All three antibodies exhibited similar blocking patterns, and anti-
GII.4-1987-G1 is shown as a representative (Fig. 8A). Since GII.4-
2006(87A.2), GII.4-2006(87A.3), and GII.4-2006(87A.4)
do not bind anti-GII.4-1987-G1, -G4, or -G5, it stands to reason
that these MAbs cannot be blocking antibodies for these chimeras.
From these data, we determined that in addition to amino acids
296 to 298, which have previously been shown to modulate anti-
genicity, amino acids 294, 368, and 372 are important for the
blockade response to GII.4-1987.
We also determined whether a known GII.4-2006 blocking an-
tibody was able to retain the ability to block our four epitope A
chimeras. We performed a CHO blockade assay to determine if
anti-GII.4-2006-G7, a mouse MAb identified by Lindesmith et al.
(28) to block GII.4-2006 interaction but not GII.4-1987 interac-
tion with HBGAs, could block HBGA interaction with GII.4-
2006(87A.1), GII.4-2006(87A.2), GII.4-2006(87A.3), and
GII.4-2006(87A.4). While anti-GII.4-2006-G7 was able to block
H3 interaction with GII.4-2006, GII.4-2006(87A.3), and GII.4-
2006(87A.4), it was unable to block HBGA binding to GII.4-
1987, GII.4-2006(87A.1), and GII.4-2006(87A.2) (Fig. 8B).
Taken together, this indicates that epitope A amino acids repre-
sent a blocking antibody epitope that is undergoing antigenic vari-
ation. The epitope encoded in both GII.4-1987 and GII.4-2006 is
targeted by antibodies that block the homotypic VLP but not the
heterotypic response.
GII.4-2006(87A.1) exhibited increased reactivity with GII.4-
1987 polyclonal mouse sera (Fig. 9A). To determine the degree to
which epitope A amino acids contribute to the overall GII.4-1987
blockade response, we performed a blockade assay comparing the
ability of GII.4-1987 polyclonal mouse sera to block H3 interac-
tion with GII.4-1987, GII.4-2006, and GII.4-2006(87A.1) VLPs
(Fig. 9B). The GII.4-1987 polyclonal serum BT50 concentration
for interaction between H3 and GII.4-1987 was 1:160 (0.7% sera),
while the BT50 for GII.4-2006(87A.1) was 1:40 (2.5% sera).
GII.4-2006 did not have a mean BT50 even at the highest concen-
tration of GII.4-1987 polyclonal sera tested (1:10); however, some
individual replicates in the assays performed did have a BT50, and
those that did not were assigned a BT50 of 1:5 (20% sera) (Fig. 9C).
By one-way ANOVA, BT50 values for GII.4-1987 and GII.4-
2006(87A.1) were not significantly different. GII.4-2006 was
significantly different from both GII.4-1987 and GII.4-
2006(87A.1) (P  0.05). Overall, these results indicate that
epitope A amino acids account for approximately 25% of the an-
FIG 7 GII.4-2006(87A.4) reactivity with anti-GII.4 MAbs. Anti-GII.4-1987
and -2006 IgG was diluted to 2 g/ml and assayed by EIA for reactivity with
GII.4-1987, GII.4-2006, and GII.4-2006(87A.4) VLPs. An amino acid resi-
due from GII.4-1987 was inserted into the GII.4-2006 backbone at position
294 to create GII.4-2006(87A.4). Bars represent the mean optical density
values with standard errors of the means. The dashed line represents 3 times
the background level of binding and indicates a positive signal.
TABLE 1 Relative reactivity of chimeric versus parental homotypic VLPs
MAb
Binding scorea
GII.4-1987 GII.4-2006 GII.4-2006(87A.1) GII.4-2006(87A.2) GII.4-2006(87A.3) GII.4-2006(87A.4)
GII.4-1987-G1 4 1 4 2 1 0
GII.4-1987-G2 4 0 1 0 0 0
GII.4-1987-G3 4 1 1 0 1 0
GII.4-1987-G4 4 1 4 0 0 0
GII.4-1987-G5 4 0 4 0 0 0
GII.4-2006-G2 1 4 2 3 4 4
GII.4-2006-G3 0 4 1 0 4 4
GII.4-2006-G4 0 4 0 0 4 4
GII.4-2006-G7 0 4 1 2 4 4
a For anti-GII.4-1987 MAbs, binding of chimeric and parental GII.4-2006 VLPs was compared to that of GII.4-1987 VLPs. For anti-GII.4-2006 MAbs, binding of chimeric and
parental GII.4-1987 VLPs was compared to that of GII.4-2006 VLPs. Scoring is as follows. VLPs that exhibited 0 to 5% of the binding level of the homotypic parental VLP (GII.4-
1987 or GII.4-2006) received a score of 0, 6 to 25% received a score of 1, 26 to 50% received a score of 2, 51 to 75% received a score of 3, and 76% or higher received a score of 4.
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tibody blockade response encoded within GII.4-1987 mouse poly-
clonal sera.
GII.4-2006(87A.1) displayed increased reactivity with 1988
GII.4 NoV outbreak human sera compared to GII.4-2006 (Fig.
10A). To determine whether epitope A amino acids contribute to
the GII.4-1987 blockade response in humans, we performed a
blockade assay comparing the ability of 1988 GII.4 NoV outbreak
human serum samples to block CHO interaction with GII.4-1987,
GII.4-2006, and GII.4-2006(87A.1). Since we were interested in
the contribution of epitope A amino acids to the GII.4-1987
blockade response, we chose to utilize nine human serum samples
that had the ability to block CHO interaction with the GII.4-1987
VLP (8, 29). Overall, the human serum samples were able to block
GII.4-1987 most efficiently and, with the exception of one indi-
vidual, were able to block GII.4-2006(87A.1) more efficiently
than GII.4-2006, although differences were not significant. When
all nine serum samples were averaged at each time point, the same
trend was seen (Fig. 10B). GII.4-1987 was blocked most efficiently
at all dilutions. GII.4-2006(87A.1) and GII.4-2006 were blocked
to similar levels, although GII.4-2006(87A.1) was blocked to a
greater degree than GII.4-2006 at all sera dilutions. We then com-
pared the BT50s (dilutions at which 50% of the VLP-CHO inter-
action is blocked compared to the control) for GII.4-1987, GII.4-
2006(87A.1), and GII.4-2006. The average BT50 values for
GII.4-1987, GII.4-2006(87A.1), and GII.4-2006 were 1:1,600,
1:800, and 1:400, respectively, indicating significant differences
for BT50 values between GII.4-1987 and GII.4-2006 (P  0.05) but
not between GII.4-2006(87A.1) and GII.4-1987 or GII.4-2006
(Fig. 10C). Together, these data suggest that epitope A contributes
to the global GII.4-1987 blockade response in mice and humans.
In vaccinated mice, epitope A accounts for approximately 25% of
the total blockade response between GII.4-1987 and GII.4-2006.
Using GII.4-1987 human antisera, we can detect clear differences
in blockade responses using time-ordered VLPs. However, be-
cause of variation among human samples and unknown preexpo-
sure histories, additional human serum samples will be needed to
detect significant differences in the blockade activity that targets
individual epitopes.
DISCUSSION
GII.4 NoVs exhibit epochal evolution, whereby major circulating
strains give rise to emergent strains, likely due to escape from herd
immunity (15, 29, 43). Evidence supporting this includes greater
positive selection in capsid P2 subdomain amino acids than in the
rest of the capsid protein, robust data exhibiting altered antigenic-
ity and HBGA binding over time in VLPs of major outbreak and
pandemic GII.4 strains, and the identification of strain-specific
potentially neutralizing antibodies in GII.4 NoVs (15, 28, 29).
Similar to GII.4 NoVs, influenza A undergoes antigenic variation
as mutations in the hemagglutinin 1 (HA1) domain of HA genes
drive escape from the existing herd immunity (18, 24, 25). Addi-
tionally, amino acids in the GII.4 NoV P2 region, which interact
with antibodies and binding ligands, undergo positive selection
similar to the mechanism in influenza whereby HA interacts with
antibodies and sialic acid and also contains many amino acids
undergoing positive selection (7, 24). Individual epitopes in other
viruses, like influenza, have been shown to lead to escape from
herd immunity (18), providing the possibility that GII.4 NoVs
undergo a similar mechanism of evolution. To provide further
support for this idea, this study used a novel mapping strategy to
identify a blockade epitope in GII.4-1987 and GII.4-2006 that
changed over time in major GII.4 outbreak strains, and we iden-
tified a specific epitope involved in modulating HBGA binding
patterns in different GII.4 strains. This is the first study to map an
antibody blockade epitope in GII.4 NoVs. These findings will fur-
ther contribute to the elucidation of mechanisms driving evolu-
tion in these viruses, provide insight into the emergence of new
epidemic variants, and provide direction for broadening the anti-
genic design and cross-blockade activity of potential vaccines for
NoVs.
Five putative epitopes were predicted via sequence analysis us-
ing 36 representative, time-ordered GII.4 stains from 1974 to 2009
to identify amino acid residues that varied consistently over time
and were exposed on the capsid surface in the P2 subdomain (16).
These varying residues were then mapped onto homology models
of each respective representative, and the structural models were
compared to find residues that map together in discrete regions of
the capsid surface. We chose to build chimeras between GII.4-
1987 and GII.4-2006 because of known differential HBGA bind-
ing and antigenicity profiles between these two strains (8, 28, 29).
By examining the reactivity of our chimeric VLPs with synthetic
HBGAs and mouse monoclonal antibodies against GII.4-1987
and GII.4-2006, we determined that epitopes A and D were im-
portant for antigenic and HBGA differences between these strains,
FIG 8 Anti-GII.4 MAb blockade of VLP/synthetic HBGA interactions. (A, B) The ability of anti-GII.4-1987-G1 (A) and anti-GII.4-2006-G7 (B) to block VLP
interaction with synthetic HBGA was measured by surrogate neutralization assay and expressed as a percentage of the control binding (100%). An antibody is
considered a “blocking antibody” if it is able to block at least 50% of the control (dashed line). Anything below the dashed line represents potential neutralization.
Error bars represent standard errors of the means from experiments run in triplicate.
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respectively. Our results suggest that changes in surface residues
drive antigenic change in GII.4 NoVs, as has been shown previ-
ously in influenza. Additionally, our results validate the utility of
using bioinformatics approaches to identify important antigenic
determinants.
Our data clearly show that amino acids 393 to 395 modulate
HBGA A and B interactions, confirming earlier observations by
our lab and others (2, 29). When we exchanged amino acids in
FIG 9 GII.4-1987 mouse polyclonal serum blockade. (A) GII.4-1987 poly-
clonal mouse sera was diluted 1:1,000 and assayed by EIA for reactivity with
GII.4-1987, GII.4-2006, and GII.4-2006(87A.1) VLPs. Bars represent the
mean optical density values with standard errors of the means. The dashed line
represents 3 times the background level of binding and indicates a positive
signal. (B) GII.4-1987 polyclonal mouse serum blockade of GII.4 VLP/syn-
thetic HBGA interactions. Ability of GII.4-1987 polyclonal mouse sera to
block VLP/synthetic CHO was measured by surrogate neutralization assay and
expressed as a percentage of the control binding (100%). An antibody is con-
sidered a “blocking antibody” if it is able to block at least 50% of the control
(dashed line). Anything below the dashed line represents potential neutraliza-
tion. Error bars represent standard errors of the means from experiments run
in triplicate. (C) GII.4-1987 polyclonal mouse serum BT50 values for GII.4-
1987, GII.4-2006, and GII.4-2006(87A.1). Blocking titers of GII.4-1987
mouse polyclonal sera were determined as the serum concentration at which
50% of the VLP/synthetic HBGA was blocked. Box and whiskers plots repre-
sent the mean serum concentration at which BT50 was achieved for each VLP.
FIG 10 1988 human outbreak serum blockade. (A) 1988 human outbreak sera was
diluted1:500andassayedbyEIAforreactivitywithGII.4-1987,GII.4-2006,andGII.4-
2006(87A.1) VLPs. Bars represent the mean optical density values with standard
errorsofthemeans.Thedashedlinerepresents3timesthebackgroundlevelofbinding
and indicates a positive signal. (B) 1988 human outbreak serum blockade of GII.4
VLP/synthetic HBGA interactions. The ability of human sera to block VLP/synthetic
CHO was measured by surrogate neutralization assay and expressed as a percentage of
the control binding (100%). An antibody is considered a “blocking antibody” if it is
able to block at least 50% of the control (dashed line). Anything below the dashed line
represents potential neutralization. Error bars represent standard errors of the means
from experiments run in triplicate. (C) 1988 human outbreak serum BT50 values for
GII.4-1987, GII.4-2006, and GII.4-2006(87A.1). Blocking titers of human sera were
determinedastheserumconcentrationatwhich50%oftheVLP/syntheticHBGAwas
blocked. Box and whiskers plots represent the mean serum concentration at which
BT50 was achieved for each VLP.
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positions 393 to 395 between GII.4-1987 and GII.4-2006, we ob-
served a significant decrease in interaction between GII.4-
2006(87D) and HBGAs A and B compared to GII.4-2006 and a
significant increase in interaction between these HBGAs and
GII.4-1987(06D) compared to GII.4-1987, indicating that these
amino acids influence interaction with A and B CHOs. However,
we also noticed that the interaction profile of GII.4-1987(06D)
was very different from that of the GII.4-2006 parent, suggesting
that other amino acids contribute to A and B interactions as well.
Teasing apart these interactions without a crystal structure can be
complex. While modeling programs can be used to provide pre-
dictions about VLP-CHO interactions, these methods rely upon
models based on previously solved structures. Studying the differ-
ences between GII.4 NoV strains has been impeded by the exis-
tence of only two GII.4 crystal structures, VA387, which models
GII.4-1997 complexed with CHOs A and B, and Hunter 2004,
bound to several CHOs. These structures were used to assemble
homology models for GII.4-1987 and GII.4-2006. Recognizing the
limitations inherent in this approach, our models identified po-
tential mechanisms that explain increased GII.4-1987(06D) in-
teractions with HBGA B compared with GII.4-2006. Structural
homology models for GII.4-1987, GII.4-2006, and GII.4-
1987(06D) predicted subtle differences in the positioning of res-
idues 393 to 395 in a surface-exposed loop (Fig. 11A) and in polar
interactions among binding pocket amino acids in sites 1 and 2
(residues 342 to 347, 374, 390 to 395, and 440 to 444) of GII.4-
2006 and GII.4-1987(06D) and in CHO B (Fig. 11B to F). Im-
portantly, direct interactions between the CHO and residues 393
to 395 were not observed; however, rearrangement of polar inter-
actions among residues 390, 393, and 395 (Fig. 11B) occurred,
which may slightly juxtapose the interactions in the binding
pocket. This suggests that these residues have long-range effects
on polar interactions in the binding pocket. Variation in the loop
programmed specific differences in the GII.4-1987(06D) ability
to (i) form a new hydrogen bond between the fucose of CHO B
and amino acid 343 (Fig. 11C), (ii) terminate two hydrogen bonds
from residue 345 and CHO B (Fig. 11D), and (iii) form new hy-
drogen bonds between residues 343 and 444 (Fig. 11E) and be-
FIG 11 Homology models comparing GII.4-1987, GII.4-2006, and GII.4-1987(06D). (A) Overlay of binding pocket of GII.4-1987 (yellow), GII.4-2006
(purple), and GII.4-1987(06D) (gray). Side chains are shown for residues in sites 1 and 2 (residues 342 to 347, 374, 390 to 395, and 440 to 444). Residues 393
to 395 are shown in teal [GII.4-1987(06D)], orange (GII.4-1987), and red (GII.4-2006). (B) Residue 390 (yellow) forms a hydrogen bond with residue 395
(yellow) in GII.4-1987(06D) that is not found in GII.4-2006. GII.4-2006 residues 393 and 395 form hydrogen bonds not found in GII.4-1987(06D). (C)
Residue 343 (yellow) forms a hydrogen bond (red arrow) with the FUC of HBGA B (orange) in GII.4-1987(06D) but not with that of GII.4-2006. (D) Three
hydrogen bonds are formed between residue 345 (yellow) and the FUC of HBGA B in GII.4-2006, but only one is formed with GII.4-1987(06D). (E) Residues
343 and 444 (both yellow) share a hydrogen bond in GII.4-1987(06D) but not in GII.4-2006. (F) Residue 442 (yellow) participates in hydrogen bonding with
the FUC of HBGA B in GII.4-1987(06D) but not with that of GII.4-2006. In GII.4-1987(06D), residue 442 (yellow) also forms a hydrogen bond with residue
443, which is not found in GII.4-2006.
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tween residue 442 and CHO B (Fig. 11F). Together, these altered
polar interactions are predicted to stabilize binding of CHOs
within the binding site, allowing GII.4-1987(06D) to exhibit
stronger binding to CHO B and potentially to H3. However, we
stress that the crystal structures of more GII.4 strains bound to
CHOs are needed to further address these predictions. Other
groups have suggested additional P2 amino acids that may mod-
ulate HBGA A and B binding. Tan et al. identified amino acid 346
as contributing to HBGA A and B interactions (45). Because this
residue varies between GII.4-1987 and GII.4-2006, it is possible
that amino acid 346 also modulates A and B binding; however, we
did not test this possibility in this study, and this residue did not
participate in direct polar interactions in our homology models.
Yang et al. reported I389 as a single amino acid residue important
for HBGA A binding (48). While this amino acid does not con-
tribute to the differences in HBGA A and B binding between
GII.4-1987 and GII.4-2006, as both strains carry I389, we cannot
rule out the possibility that this residue contributes to HBGA
binding in other GII.4 strains. However, Shanker et al. also found
no evidence that residue 389 would contribute to HBGA A bind-
ing in GII.4-2004 (41).
Epitope A amino acids (294, 296 to 298, 368, and 372) change
over time and map to the same area of the capsid surface, likely
forming a noncontiguous conformational epitope. Influenza vi-
rus and HIV provide examples of viruses that have variable, non-
contiguous conformational epitopes that change over time, re-
sulting in viruses that are able to escape the immune response (10,
20, 49, 50). Our data demonstrate that epitope A amino acids
collectively comprise a blocking antibody epitope for both GII.4-
1987 and GII.4-2006, suggesting that the surrounding landscape
and conformational changes associated with amino acid variation
greatly impact antigenicity. Variation likely reshapes the surface of
the P2 region, altering the affinity with which different MAbs bind
and neutralize the virus; however, additional GII.4 crystal struc-
tures coupled with MAb are essential for understanding the mo-
lecular basis of antibody binding and blockade and likely essential
for illuminating the mechanism of escape from herd immunity.
While predicted epitope A also includes amino acid 296, this res-
idue is conserved between GII.4-1987 and GII.4-2006, so our cur-
rent work does not address the antigenic consequences of changes
to residue 296. However, Allen et al. (2) demonstrated that amino
acids 296 to 298 were important antigenic determinants between
pre-2002 and post-2002 GII.4 strains, although they did not eval-
uate CHO blockade. Our data corroborate the importance of
these amino acids in GII.4 antigenic changes over time. Introduc-
tion of smaller subsets of epitope A amino acids, as in GII.4-
2006(87A.2), GII.4-2006(87A.3), and GII.4-2006(87A.4),
did not yield gains in binding to anti-GII.4-1987 MAbs for the
chimeric VLPs tested, suggesting that all five epitope A amino acid
changes in combination are needed to gain robust binding phe-
notypes to the anti-GII.4-1987 MAbs tested. While speculative,
some flu epitopes are proposed to evolve by epochal evolution
characterized by drift modified by mutations of large effect; sim-
ilar mechanisms may be operating during GII.4 persistence in
human populations (24). While it is possible that creating addi-
tional combinations of these five amino acids would yield a com-
bination that accounts for the gain in binding to anti-GII.4-1987
MAbs, we argue that it is more likely that these noncontiguous
amino acids constitute a conformational epitope in which they
contribute, in concert, to the gain in binding to anti-GII.4-1987
MAbs. We do not exclude the possibility that additional amino
acids may contribute to interactions with anti-GII.4-1987 and
anti-GII.4-2006 MAbs. Importantly, based on sequence align-
ment data, epitope A is still evolving in the currently circulating
Minerva variant, GII.4-2009 New Orleans. This suggests that this
epitope may also constitute an important blocking epitope in fu-
ture epidemic GII.4 strains, thus monoclonal antibodies against
contemporary GII.4-2009 strains may provide greater resolution
in understanding the potential mechanisms driving antigenic
variation and antibody blockade escape over time. To our knowl-
edge, this is the first study utilizing a panel of time-ordered chi-
meric viruses with exchanged epitopes to study these processes;
however, this approach may be highly relevant to studying anti-
genic variation in other viruses, including influenza and HIV.
Because human NoVs lack a viable cell culture model, antibody
neutralization potential is measured in a surrogate neutralization
assay, the CHO blockade assay (21, 28). This assay measures an
antibody’s ability to block the interaction between immobilized
HBGA and a particular VLP. Reeck et al. showed a correlation
between the ability of antibodies to block VLP-HBGA interaction
in this assay and protection from symptomatic Norwalk virus in-
fection, demonstrating that the blockade assay is a relevant surro-
gate assay that measures a component of protective immunity
(39). We showed that epitope A is a significant blockade epitope.
Using anti-GII.4-1987-G1, -G4, and -G5 MAbs, we demonstrated
that residues 294, 297 to 298, 368, and 372 work in concert to
account for the GII.4-1987 blockade response for these antibod-
ies. Using anti-GII.4-2006-G7, we demonstrated that amino acids
297 to 298 account for the GII.4-2006 blockade response for this
antibody. GII.4-2006(87A.1) and GII.4-2006(87A.2), which
both contain changes at these residues, were not blocked by anti-
GII.4-2006-G7, but this antibody blocked VLP-HBGA interaction
for chimeras GII.4-2006(87A.3) and GII.4(87A.4), which did
not contain substitutions at residue 297 or 298. Approximately
25% of the total blockade response for GII.4-1987 polyclonal
mouse sera was targeted against epitope A based on comparison of
the CHO blockade potential of the parental GII.4-1987 to that of
GII.4-2006. This result suggests that there are either additional
unidentified blockade epitopes present for GII.4-1987 or addi-
tional unidentified residues that contribute to the overall anti-
genic variation in epitope A. This approach may be useful in fu-
ture studies to predict the number of potentially neutralizing
epitopes for each particular strain and the relative importance of
each epitope in contributing to blocking antibody response over
time.
Using GII.4 NoV human outbreak sera, we demonstrated that
epitope A is a potential blockade epitope not only in mice but also
in humans. Results gleaned from human data underscore the im-
portance of individual variation and previous exposure history in
the immune response to different GII.4 NoV strains. Mouse poly-
clonal serum data, produced in a background with no previous
exposure history or genetic diversity, yielded clear differences in
blockade among GII.4-1987, GII.4-2006(87A.1), and GII.4-
2006, in which GII.4-1987 and GII.4-2006(87A.1) were blocked
but GII.4-2006 was not. Human sera, on the other hand, was able
to block VLP-CHO interactions with GII.4-1987, GII.4-
2006(87A.1), and GII.4-2006, though with differences in the
overall BT50 values. While the human outbreak sera were able to
detect significant differences in BT50 values between GII.4-1987
and GII.2006, this sera was unable to distinguish significant dif-
Debbink et al.
1224 jvi.asm.org Journal of Virology
ferences at the level of a single varying epitope. However, the over-
all trend showed that the human outbreak sera blocked GII.4-
2006(87A.1) more efficiently than GII.4-2006 at every dilution
point. This suggests that epitope A likely contributes to the human
blockade response in GII.4-1987 but that additional human se-
rum samples are needed to dissect the overall contribution of an
individual epitope. The differences in blockade between mouse
and human sera may be due to varied NoV exposure histories
from the human serum donors. Ogata et al. found that previous
influenza vaccination resulted in greater levels of neutralizing an-
tibodies against the newly emergent human H5N2 avian influenza
virus (35). In addition, Lee et al. found that previous exposure to
pre-1957 H1N1 strains was able to provide some cross-
neutralizing protection from the 2009 H1N1 strain but not from a
2007 strain (27). This suggests that in some cases, previous expo-
sure history may provide subtle to substantial levels of protection
from related but distinct viral strains on an individual level. Since
GII.4 NoVs and influenza exhibit similar evolutionary dynamics,
previous exposure to NoV may provide protection from specific
strains but not others. Our data provide evidence that epitope A
accounts for up to 25% of the GII.4-1987 blockade response and
suggests that there are additional blockade epitopes for GII.4-
1987.
Our approach of using bioinformatics predictions to identify
putative GII.4 NoV epitopes coupled with using our panel of chi-
meric and parental VLPs, time-ordered mouse MAbs, and syn-
thetic CHOs in ELISA-based assays to validate our predictions
offers a powerful method to elucidate the mechanisms driving
GII.4 NoV evolution in the absence of a cell culture or small-
animal model. Despite evidence that preferential HBGA binding
patterns and antigenicity in GII.4 NoVs change over time, results
among different labs vary and are difficult to directly compare due
to differences that may exist among VLPs, P particles, and P
dimers, differences in protein concentrations used in ELISA-
based assays, and lot number differences in the reactivity of com-
mercial biotinylated HBGAs. Variation in CHO binding levels
among assays in this study is due to the differing reactivity among
batches of commercially available synthetic biotinylated CHOs;
however, due to the low supply of these reagents, this is unavoid-
able without altering the amount of CHO used in each experi-
ment. However, it is clear that mutations outside the conserved
CHO binding residues contribute to the antigenic and HBGA
binding differences apparent over time. Future work will seek to
validate our other predicted epitopes by expanding the epitopes to
include surrounding amino acids and by building and character-
izing additional chimeras in the GII.4-2002 Farmington Hills
background.
GII.4 NoVs are significant human pathogens that cause con-
siderable morbidity and mortality worldwide. The identification
of highly significant, varying antigenic epitopes that influence
VLP-ligand interaction provides important new insights into vac-
cine design and the development of therapeutics that target noro-
virus virions. For example, our data predict that vaccines derived
from GII.4-1987(06A) or GII.4-2006(87A) should greatly
broaden the breadth of the cross-antigenic and cross-blockade
response against time-ordered GII.4 NoV. Our data predict that
GII.4-2006(09A) vaccines would induce stronger blockade re-
sponses against contemporary GII.4 strains than GII.4-2006 VLP
vaccines. These experiments are under way. Finally, we anticipate
that a full understanding of the varying antigenic and blockade
epitopes of GII.4 NoV may not only help to predict the emergence
of new epidemic strains but also simultaneously identify key re-
formulations in vaccine design that will protect the public health
against contemporary and emerging epidemic strains of the fu-
ture.
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